摘要
目的研究益气散结汤联合氟尿嘧啶对食管癌患者的治疗效果及对转化生长因子-β_(1)(transforming growth factor-β_(1),TGF-β_(1))及胰岛素样生长因子-1(insulin like growth factor-1,IGF-1)的影响。方法选取2018年1月~2019年12月收治的80例行手术治疗的食管癌患者为研究对象,随机分为试验组(n=40)与对照组(n=40)。对照组术后给予氟尿嘧啶治疗,试验组术后给予益气散结汤联合氟尿嘧啶治疗。比较两组患者治疗前后IGF-1、TGF-β_(1)表达水平的变化,分析两组患者临床疗效和不良反应的发生率。结果试验组总有效率(70.00%)明显高于对照组(52.50%),差异具有统计学意义(P<0.05);治疗前,两组患者血清TGF-β_(1)、IGF-1表达水平无明显差异(P>0.05);治疗后,两组患者血清中TGF-β_(1)、IGF-1表达水平均明显降低(P<0.05),且试验组降低更明显(P<0.05);试验组恶心呕吐、白细胞降低、口腔炎、腹泻等不良反应发生率明显低于对照组(P<0.05)。结论益气散结汤联合氟尿嘧啶治疗食管癌的临床疗效显著,能够有效降低患者血清TGF-β_(1)及IGF-1水平,且不良反应少。
Objective To investigate the effect of Yiqi Sanjie Decoction combined with fluorouracil on esophageal cancer patients and the effect on serum insulin-like growth factor 1(IGF-1)and transforming growth factor β_(1)(TGF-β_(1)).Methods From January 2018 to December 2019,80 patients with esophageal cancer admitted to our hospital for routine surgical treatment were randomly divided into experimental group(n=40)and control group(n=40).The control group was treated with fluorouracil after operation,and the experimental group was treated with Yiqi Sanjie Decoction combined with fluorouracil after operation.The changes of IGF-1、TGF-β_(1) expression level before and after treatment were compared,and the clinical efficacy and the incidence of adverse reactions in the two groups.Results The total effective rate of the experimental group(70.00%)was significantly higher than that of the control group(52.50%)(P<0.05);Before treatment,there was no significant difference in serum TGF-β_(1)、IGF-1 expression level between the two groups(P>0.05);After treatment,the serum expression level of the two groups decreased significantly(P<0.05),and the experimental group decreased more significantly(P<0.05);The incidence of adverse reactions such as nausea and vomiting,leukopenia,stomatitis,diarrhea and so on in the experimental group was significantly lower than that in the control group(P<0.05).Conclusion Yiqi Sanjie Decoction combined with fluorouracil in the treatment of esophageal cancer has a significant clinical effect,can effectively reduce the serum TGF-β_(1) and IGF-1 level of patients with less adverse reactions.
作者
贺波
HE Bo(Oncology Department,Qingyang People's Hospital,Qingyang 745000,China)
出处
《中国处方药》
2022年第8期95-97,共3页
Journal of China Prescription Drug